Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2016 /
Comparison of three different PD-L1 diagnostic tests shows a high degree of concordance

16th - 20th Apr 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 26.04.16
Views: 1989

Dr Marianne Ratcliffe - AstraZeneca, UK

Dr Marianne Ratcliffe speaks with ecancertv at AACR 2016 about her work in establishing the comparative efficacy of three commercially available PDL-1 assays.

With pembrolizumab gaining increasing traction as a therapy across an array of cancer types, many different assays are available from multiple manufacturers but with little data available on their interchangability.

Dr Ratcliffe reports a high degree of concordance between three assays, and highlights the ongoing debate of using PDL-1 positive or negative results to influence patient medication as an area requiring further consideration with hopes to reach a broad agreement of test suitability.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation